Published May 2021, in JAMA Network
To the Editor We would like to add 2 treatment options not mentioned in the recent extensive review on the management of Crohn disease by Drs Cushing and Higgins1 because an estimated 6 million to 8 million people worldwide have inflammatory bowel disease (IBD), of whom the majority live in lower- and middle-income countries (LMICs) or lack access to health insurance and drugs.2 The affordability and accessibility to monoclonal biologic therapies for these patients with IBD leaves local gastroenterologists with limited treatment options.3 Under the United Nations Good Health and Well-Being Sustainable Development Goal, the World Health Organization has made accessibility to medicine one of its priorities. Therefore, it is important to mention and investigate accessible and affordable therapies, especially for those who are treating patients with IBD without significant resources.